ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, de novo and acquired resistance to IM in CML seem to have a convergence point in the Bcr/Abl overexpression, which is a common feature of the two last phases of the disease [15]–[17].